Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227193 | 0.87 | MAPT (0.51) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL3954275 | 0.85 | KMT2A (0.66) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL4198980 | 0.84 | MEN1 (0.47) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL11982909 | 0.84 | KMT2A (0.45) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL4194871 | 0.82 | KMT2A (0.45) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL4208885 | 0.78 | MEN1 (0.44) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL13136441 | 0.77 | KMT2A (0.44) | KMT2AMEN1CYP3A4HIF1ANPSR1 | |
| SCHEMBL15358899 | 0.77 | KMT2A (0.42) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL13356469 | 0.75 | MAPT (0.49) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL13356431 | 0.75 | MAPT (0.49) | KMT2AMEN1CYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753723-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113507-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | WANG WEIBO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | ABCG2, ABCB1, UGT2B7 | KMT2A 2420/4885MEN1 1972/4885CYP3A4 15/4885 |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | KIF5B, KIF2C, KIF5C | KMT2A 429/4885MEN1 3090/4885CYP3A4 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.